Notter M F, Docherty J J
Cancer Res. 1976 Dec;36(12):4394-401.
Antigens isolated from herpes simplex virus type 1, herpes simplex virus type 2, or cytomegalovirus-transformed hamster cells were tested against 66 sera from non-cancer individuals or patients with different types of cancer. By use of the microcomplement fixation procedure to quantify all antigen-antibody interactions, it was observed that 94% (p less than 0.001) of all sera from patients with squamous cell carcinoma reacted with antigens from herpes simplex virus type 1-transformed cells, while 84% (p less than 0.001) of the same sera reacted with antigen preparations from herpes simplex virus type 2-transformed cells. When sera from patients with adenocarcinoma, sarcoma, liposarcoma, and melanoma were tested against these antigens, there was no significant difference in their reactivity from sera of noncancer patients. When sera from all individuals (normal and cancer) were tested against antigens from cytomegalovirus-transformed cells, no significant reaction pattern developed. These studies are the first to describe the isolation of a reactive tumor-associated protein from herpes simplex virus-transformed cells.
从1型单纯疱疹病毒、2型单纯疱疹病毒或巨细胞病毒转化的仓鼠细胞中分离出的抗原,用66份来自非癌症个体或患有不同类型癌症患者的血清进行检测。通过使用微量补体结合程序来量化所有抗原 - 抗体相互作用,观察到鳞状细胞癌患者的所有血清中有94%(p小于0.001)与1型单纯疱疹病毒转化细胞的抗原发生反应,而相同血清中有84%(p小于0.001)与2型单纯疱疹病毒转化细胞的抗原制剂发生反应。当腺癌、肉瘤、脂肪肉瘤和黑色素瘤患者的血清针对这些抗原进行检测时,它们的反应性与非癌症患者的血清没有显著差异。当所有个体(正常和癌症患者)的血清针对巨细胞病毒转化细胞的抗原进行检测时,没有出现显著的反应模式。这些研究首次描述了从单纯疱疹病毒转化细胞中分离出一种反应性肿瘤相关蛋白。